Beam’s Breakthrough: Revolutionizing Genetic Medicine?
Beam Therapeutics Inc., a leading biotechnology company specializing in precision genetic medicines through base editing, has recently made a significant announcement. In August, the company initiated treatment for its first patient with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therapy. This therapy is currently under evaluation in a Phase 1/2 clinical trial aimed at treating […]
Caring Cross Unveils Affordable Genetic Therapy Strategies
New press release announces the role of Caring Cross, a non-profit organization, in a newly published white paper from the Innovative Genomics Institute, titled “Making Genetic Therapies Affordable and Accessible.” The white paper is the result of yearlong research and focuses on strategies to increase the affordability and accessibility of genetic therapies, including CAR-T technology […]
ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma
WEST HILLS, Calif., Jan. 24, 2023 /PRNewswire/ — ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced clearance of its first Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for IMPT-314, a bispecific “OR-Gate” autologous CAR T-cell therapy targeting the B-cell […]
Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. and CTMC, a joint venture between MD Anderson Cancer Center and National Resilience, Inc., today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen […]
Grant Awarded to Develop Genetically Engineered Stem Cell Products to Fight Gastroesophageal Cancer
NEW YORK, Nov. 9, 2022 /PRNewswire/ — The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative (GEMINI) has awarded $250,000 to Saar Gill, MD, PhD, of the University of Pennsylvania, to improve immunotherapy in gastroesophageal cancer by using the tools of genetic engineering to modify human blood-forming stem cells to produce highly specialized cancer-eating cells called […]
CAR T-Cell Therapy: Ask Dr. Alaa Ali
Alaa Ali, MD, MSC, is a clinician, instructor, and investigator in clinical and translational research at MedStar Georgetown’s Stem Cell Transplant and Cellular Immunotherapy program. In the following video, Dr. Alaa Ali explains what CAR T-cell therapy is and how it works, what the process is for creating CAR T-cells to fight cancer, the success […]
Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that a poster describing the first-in-human Phase 1 trial design for LYL797, Lyell’s ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic […]